Emerging therapies include:

• newer generation BTK inhibitors such as zanubrutinib (Tam et al. 2020) and pirtobrutinib (LOXO-305) (Mato et al. 2021)
• CAR T-cell therapy, a cellular therapy, directed against the CD19 surface molecule (Mancikova & Smida 2021)
• other emerging monoclonal

There are currently no approved therapies for CLL that specifically target acquired genomic mutations beyond TP53 dysfunction identifying a subgroup of patients where chemoimmunotherapy is contraindicated.